Sign in

DRMA on Nasdaq

Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is an American pharmaceutical preparations company based in San Diego.1 Its shares trade on Nasdaq under the symbol DRMA.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerDRMA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address3525 Del Mar Heights Rd., #322, San Diego, Ca 921302
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Successfully draw awareness to our Tome skincare brand in preparation for the launch of our first commercial products. We recently announced the name of our new skincare brand, Tome, and are working on building the brand identity for our DTC skincare products, which will represent our core value of providing consumers with skincare products that come from nature but are scientifically proven to work.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$7.8M in 2025+145% since 2020
-$15.0M-$10.0M-$5.0M02020: -$3.2M-$3.2M20202021: -$7.9M-$7.9M2021+148%2022: -$9.7M-$9.7M2022+23%2023: -$8.0M-$8.0M2023−17%2024: -$12.5M-$12.5M2024+56%2025: -$7.8M-$7.8M2025−38%
Net income45678-$7.6M in 2025+134% since 2020
-$15.0M-$10.0M-$5.0M02020: -$3.2M-$3.2M20202021: -$7.9M-$7.9M2021+144%2022: -$9.6M-$9.6M2022+22%2023: -$7.8M-$7.8M2023−19%2024: -$12.3M-$12.3M2024+58%2025: -$7.6M-$7.6M2025−38%
Fiscal year20192020202120222023202420252026
Research and development$1.6M4$3.5M5$5.7M6$4.1M7$8.2M8$2.9M8
Selling, general and admin$4.3M8$4.8M8
Operating expenses$9.7M6$8.0M7$12.5M8$7.8M8
Operating income-$3.2M4-$7.9M5-$9.7M6-$8.0M7-$12.5M8-$7.8M8
Interest$197.3K4$45.6K4
Income tax$04$05$06$07$07
Net income-$3.2M4-$7.9M5-$9.6M6-$7.8M7-$12.3M8-$7.6M8
Earnings per share-$1.694-$2.435-$13.926-$39.997-$80.328-$8.168
Earnings per share (diluted)-$39.997-$80.328-$8.168
Shares (weighted, basic)4.3M shares4153.0K shares8926.2K shares8
Shares (weighted, diluted)194.9K shares7153.0K shares8926.2K shares8

Compare Dermata Therapeutics, Inc. with another company

Corporate structure

Dermata Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Dermata Therapeutics, Inc.

  • Hoose Kyri K. Van Filed SCHEDULE 13D on Dermata Therapeutics, Inc., latest Jun 1, 2026
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on Dermata Therapeutics, Inc., latest May 13, 2026 (5 filings since Jun 1, 2023)
  • BIGGER CAPITAL FUND L P Filed SCHEDULE 13G/A on Dermata Therapeutics, Inc., latest Apr 22, 2026 (3 filings since Dec 30, 2025)
  • PROEHL GERALD T Filed SCHEDULE 13D/A on Dermata Therapeutics, Inc., latest Feb 23, 2026 (10 filings since May 5, 2022)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Dermata Therapeutics, Inc., latest Feb 18, 2026 (7 filings since Feb 14, 2024)
  • HALE DAVID F Filed SC 13D/A on Dermata Therapeutics, Inc., latest Mar 31, 2023
  • Dermata Therapeutics, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Dermata Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.5M8 Dec 31, 2025$3.2M8 Dec 31, 2024+137.9%

Properties, in its own words

Our mailing address is 3525 Del Mar Heights Rd., #322, San Diego, California 92130. In February 2026, we leased a small office location on a month-to-month basis, available for use by any of our employees. All of our employees work remotely. We believe our virtual work structure and small office space is adequate to meet our current needs, although we may seek to negotiate a new lease or evaluate additional or alternate space for our operations. We believe appropriate alternative space would be readily available on commercially reasonable terms.

Item 2 of the 10-K filed Mar 26, 2026.3

Leadership

Who has led Dermata Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gerald T. Proehl2021–now

Chair

  1. Gerald T. Proehl2021–now

President

  1. Gerald T. Proehl2021–now

Chief financial officer

  1. Thomas Insley2021
  2. Hoose Kyri K. Van2021–now
2025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerKyri K. Van Hoose named Jun 12, 2023 to Jan 7, 202625
  • Executive OfficerMaria J. Bedoya Toro Munera named Jun 12, 2023 to Jan 7, 202625

Timeline

  1. Aug 17, 20268-K Entered a material agreement; Unregistered sale of shares; Other events26
  2. Aug 11, 20268-K Results of operations27
  3. Aug 5, 20268-K Other events28
  4. May 27, 20268-K Executive or director change; Shareholder vote29
  5. May 13, 20268-K Results of operations30
  6. Mar 26, 20268-K Results of operations31
  7. Feb 25, 20268-K Executive or director change32
  8. Feb 3, 20268-K Change of auditor33
  9. Jan 27, 20268-K Other events34
  10. Dec 29, 20258-K Entered a material agreement; Unregistered sale of shares; Other events35
  11. Nov 18, 20258-K Ended a material agreement36
  12. Nov 14, 20258-K Results of operations; Regulation FD disclosure37
  13. Aug 12, 2021New chief executive Gerald T. Proehl becomes CEO12

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202638

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results27
  2. May 13, 2026Reported quarterly or annual results30
  3. Mar 26, 2026Reported quarterly or annual results31
  4. Nov 14, 2025Reported quarterly or annual results37
  5. Aug 13, 2025Reported quarterly or annual results39
  6. May 14, 2025Reported quarterly or annual results40
  7. Mar 17, 2025Reported quarterly or annual results41
  8. Nov 14, 2024Reported quarterly or annual results42

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

311 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 75 major events, 78 insider forms, 27 large holders, 5 private raises, 105 other. The latest 20:

  1. Oct 9, 2026S-3 EDGAR
  2. Aug 18, 20264 EDGAR
  3. Aug 18, 20264 EDGAR
  4. Aug 17, 20268-K EDGAR
  5. Aug 17, 202625-NSE EDGAR
  6. Aug 11, 202610-Q EDGAR
  7. Aug 11, 20268-K EDGAR
  8. Aug 5, 20268-K EDGAR
  9. Jun 16, 20264 EDGAR
  10. Jun 4, 2026S-8 EDGAR
  11. Jun 1, 2026SCHEDULE 13D EDGAR
  12. May 29, 2026EFFECT EDGAR
  13. May 29, 2026424B3 EDGAR
  14. May 27, 20268-K EDGAR
  15. May 27, 2026CORRESP EDGAR
  16. May 22, 2026S-3/A EDGAR
  17. May 13, 202610-Q EDGAR
  18. May 13, 20268-K EDGAR
  19. May 13, 2026SCHEDULE 13G/A EDGAR
  20. Apr 22, 2026SCHEDULE 13G/A EDGAR

The 311 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 2 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 16, 2026Scott Kathleen D.DirectorSale11$1.19$13Form 4
Feb 17, 2026Bedoya-Toro Munera Maria ESVP, Regulatory AffairsBuy1,000$1.27$1.3KForm 4
Nov 23, 2021PROEHL GERALD TPRESIDENT, CHAIRMAN, CEOBuy20,000$2.40$48.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Christopher J. NardoPh.D.$367.0K$537.1K49
2025Kyri K. Van Hoose48$346.6K$508.5K49
2025Gerald T. Proehl67$280.0K$472.5K49
2024Senior Vice PresidentChief Financial Officer$328.5K$464.6K49
2024President and Chief Executive Officer$280.0K$462.0K49

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 29, 2025Raised $4.1 million in a private offering of equity Form D: 14 investors so far Form D
  2. Jan 21, 2025Raised $2.5 million in a private offering of equity Form D: 8 investors so far Form D
  3. Sep 17, 2024Raised $3.5 million in a private offering of securities Form D: 1 investor so far Form D
  4. May 26, 2023Filed a private offering of securities Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Geode Capital Management, LLC20,203$26.1K0.0%−28,131
Welch & Forbes LLC20,000$25.8K0.0%No change
State Street Corp18,747$24.2K0.0%New
UBS Group AG16,796$21.7K0.0%−18,812
Susquehanna International Group, Llp15,989$20.6K0.0%New
XTX Topco Ltd14,787$19.1K0.0%New
Advisory Alpha, LLC10,000$12.9K0.0%New
Tower Research Capital LLC (TRC)3,860$5.0K0.0%+3,144
MCF Advisors LLC1,732$2.2K0.0%No change
Barclays PLC270$3480.0%New
SBI Securities Co., Ltd.101$1300.0%No change
Highline Wealth Partners LLC26$340.0%New
Morgan Stanley2$30.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Dermata Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDermata Therapeutics, Inc.1
  • CIK0001853816
  • Employer ID (EIN)86-32187363
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3525 Del Mar Heights Rd., #322, San Diego, CA 921301
  • Phone(858)-223-08821
  • Shares outstanding4,022,143 as of Aug 10, 202610
  • Public float$3.1M as of Jun 30, 20253
  • AuditorCBIZ CPAs P.C, San Diego, California PCAOB ID 199; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceApr 2, 20211
  • Filings367 in all: 4 (89), 8-K (77), CORRESP (21), 10-Q (16), UPLOAD (14), 3 (13), EFFECT (12), 424B3 (11)1
    All 42 form types

    S-3 (9), SCHEDULE 13G/A (8), DEF 14A (7), S-1/A (7), SCHEDULE 13D/A (7), DEFA14A (6), PRE 14A (6), 10-K (5), 424B5 (5), S-1 (5), S-8 (5), 424B4 (4), ARS (4), D (4), SC 13D/A (4), SCHEDULE 13G (4), SEC STAFF LETTER (3), DRS (2), FWP (2), SC 13D (2), SC 13G (2), 10-K/A (1), 25-NSE (1), 8-A12B (1), CERT (1), D/A (1), DRS/A (1), DRSLTR (1), POS EX (1), RW (1), S-1MEF (1), S-3/A (1), SC 13G/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 17, 2026
    Latest 8-K (8-K) Aug 17, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareDRMANasdaq
Warrants, exercisable for one share of Common StockDRMAWNasdaq

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Dermata Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 71 risks under these headings, as written.3

  • Risks Related to Our Financial Position and Need for Capital
  • We are a pre-commercial stage company with a limited operating history.
  • We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.
  • We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our products.
  • The reports of our independent registered public accounting firm for the fiscal years ended December 31, 2025, and 2024, contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
  • Changes in tax laws may materially adversely affect our business financial condition, results of operations and cash flows.
  • Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.
  • Disruptions to our distribution operations could adversely affect our ability to deliver our products to consumers and customers.
  • Adverse global conditions, including economic uncertainty, may negatively impact our financial results.
  • Risks related to the skincare industry
  • Our shift from an Rx regulatory framework to OTC monograph pathways could introduce significant regulatory risks that could delay or prevent product launches, require reformulation or relabeling, restrict indications or target populations, and materially increase costs.
  • The skincare industry is highly competitive, and if we are unable to compete effectively, our results will suffer.
The other 61 risks
  • Our business is dependent on the commercial success and our ability to launch and sell Tome skincare products, including our Foundational Treatment. If we are unable to successfully launch, commercialize and sell our Foundational Treatment, our results of operations and financial condition will be materially harmed.
  • Our new product launch may not be as successful as we anticipate.
  • Any damage to our reputation or brand may materially and adversely affect our business, financial condition and results of operations.
  • Our success depends, in part, on the quality, efficacy and safety of our products.
  • The illegal distribution and sale by third parties of counterfeit versions of our products or the unauthorized diversion by third parties of our products could have an adverse effect on our net sales and a negative impact on our reputation and business.
  • Demand for our products may not increase as rapidly as we anticipate due to a variety of factors, including a weakness in general economic conditions and resistance to non-traditional treatment methods.
  • We may experience declines in average selling prices of our products which may decrease our net revenues.
  • Risks related to our growth and profitability
  • We may not be able to successfully implement our growth strategy.
  • Our growth and profitability are dependent on a number of factors.
  • We may be unable to grow our business effectively or efficiently, which would harm our business, financial condition and results of operations.
  • Acquisitions or investments could disrupt our business and harm our financial condition.
  • We expect our future quarterly and annual operating results to fluctuate for a variety of reasons, particularly as we focus on increasing consumer demand for our products. Volatility in the financial markets could also have a material adverse effect on our business.
  • Risks related to our business operations
  • A disruption in our operations could materially and adversely affect our business.
  • Our success depends, in part, on our retention of key members of our senior management team, whose continued service is not guaranteed, and ability to attract and retain qualified personnel.
  • We rely on a number of third-party suppliers, distributors and other vendors, and they may fail to produce products or to provide services that are consistent with our standards or applicable regulatory requirements, which could harm our brand reputation, cause consumer dissatisfaction or require us to find alternative suppliers of our products or services.
  • We are dependent on one supplier for the raw material used to produce the sponge powder used in our products. The termination of this contract would result in a disruption to product development, and our business will be harmed.
  • Our business may be affected by new sanctions, import restrictions, and export controls targeting Russia and other responses to Russia’s invasion of Ukraine.
  • We rely on third-party delivery service providers.
  • A disruption in the operations of our primary freight carrier or higher shipping costs could cause a decline in our net revenues or a reduction in our earnings.
  • If we fail to manage our inventory effectively, our results of operations, financial condition and liquidity may be materially and adversely affected.
  • In order to build market penetration and raise awareness of our brand and products, we will have to spend substantial cash on marketing activities, which may not ultimately prove successful or an effective use of our resources.
  • Any skincare professionals we may engage in the future will likely not be under any obligation to purchase any product from us, and business challenges at one or more of these providers could adversely affect our results of operations.
  • Risks Related to Consumer Use Studies and Product Testing
  • We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or product improvements or the generation of significant future revenues.
  • Risks related to evolving laws and regulations and compliance with laws and regulations
  • New laws, regulations, enforcement trends or changes in existing regulations governing the introduction, marketing and sale of our products to consumers could harm our business.
  • New laws, regulations, enforcement trends, or changes in existing regulations could affect the ability of our aesthetician providers in certain states to provide our treatments to consumers, any of which could have a material adverse effect on our business, financial condition, and results of operation.
  • Our facilities are subject to regulation under the FDCA and FDA implementing regulations governing the manufacture of our products. If we fail to comply with federal, state and foreign regulations, our manufacturing operations could be halted, and our business would suffer.
  • Government regulations and private party actions relating to the marketing and advertising of our products and services may restrict, inhibit, or delay our ability to sell our products and harm our business, financial condition and results of operations.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
  • As compliance with healthcare regulations becomes more costly and difficult for us or our customers, we may be unable to grow our business.
  • If we market products in a manner that violates healthcare laws, we may be subject to civil or criminal penalties.
  • Government regulation of the Internet and e-commerce is evolving, and unfavorable changes or failure by us to comply with these regulations could substantially harm our business, financial condition and results of operations.
  • Our products may cause undesirable side effects or have other unexpected properties that could limit the commercial appeal or result in post-approval regulatory action.
  • We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
  • If any of our products are approved for marketing and we are found to have improperly promoted, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.
  • We may choose not to continue developing or commercializing any of our products at any time during development or after launch, which would reduce or eliminate our potential return on investment for those products.
  • We or our current and prospective partners may be subject to product recalls in the future that could harm our brand and reputation and could negatively affect our business.
  • We may also be subject to healthcare and consumer-protection laws, regulations and enforcement and our failure to comply with those laws could adversely affect our business, operations and financial condition.
  • Our employees, independent contractors, consultants, vendors, CROs and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
  • Risks related to marketing activities
  • Use of social media may materially and adversely affect our reputation or subject us to fines or other penalties.
  • We expect that our business will rely heavily on email and other messaging services, and any restrictions on the sending of emails or messages or an inability to timely deliver such communications could materially adversely affect our net revenue and business.
  • Risks Related to Managing Our Growth, Our Employees and Our Operations
  • We will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in executing our growth strategy and managing any growth.
  • If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our products or otherwise implement our business plan.
  • We currently have limited marketing capabilities. If we are unable to establish sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize our product candidates or generate product revenue.
  • Our failure to successfully in-license, acquire, develop, and market additional products would impair our ability to grow our business.
  • Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.
  • Our operating results and liquidity needs could be negatively affected by market fluctuations and economic downturn.
  • Our business and operations would suffer in the event of failures in our internal computer systems.
  • We are increasingly dependent on information technology, and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
  • The increasing use of artificial intelligence (“AI”) in our operations and by third-party partners may create operational, compliance, and reputational risks that could adversely affect our business and results of operations.
  • Risks Related to Our Intellectual Property
  • We may not be able to obtain or enforce patent rights or other intellectual property rights that cover our products and technologies that are of sufficient breadth to prevent third parties from competing against us.
  • Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future patents.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • The complexity and uncertainty of European laws have increased in recent years.
  • If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive and time-consuming.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.
  • We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former employers or their former or current customers.
  • If our patent term expires before or soon after our products available for sale, or if manufacturers of generic or similar products successfully challenge our patents, our business may be materially harmed.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Legal proceedings

From time to time, we may be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we do not currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from important business matters and initiatives, negatively impacting our overall operations.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49